Breathing Room For BMS In Renal Cancer As Early Tecentriq Data Mixed
Latecomer Tecentriq from Roche has been making solid in roads in the lung cancer space, where it has been scrapping it out with Bristol-Myers Squibb's Opdivo and Merck & Co's Keytruda. However, early data with Tecentriq in the renal cell carcinoma (RCC) space are less than impressive. The news will be welcomed by BMS, which has Opdivo approved in advanced RCC.
You may also be interested in...
As the RCC field braces for another paradigm change, early studies combining tyrosine kinase inhibitors with PD-1/L1 inhibitors suggest the highest response rates are found with Inlyta (axitinib) as a partner.
A NICE knock-back for Ipsen's Cabometyx in renal cell carcinoma (RCC) means less pressure on BMS's embattled Opdivo, but not for long if Ipsen is willing to compromise on price, warn analysts.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.